Indian Drug Makers Face Hit Over Former Excise Duty
This article was originally published in PharmAsia News
Executive Summary
Many pharmaceutical companies in India could be faced with punitive action because they did not act quickly enough in passing on duty cuts. The National Pharmaceutical Pricing Authority rejected the industry's request they be allowed to sell out all drugs assessed at the old excise duty rate before applying the new one. The companies noted the law bars them from changing the price on drugs already packaged and ready for distribution. India's revenue department could decide to let the firms pass on the earlier excise taxes on drugs in the chain for distribution at the time of the duty change. (Click here for more
You may also be interested in...
MoCRA’s Adulteration Ambiguity And FDA’s New Cosmetic Recall Authority: Attorney Weighs In
The US FDA should use guidance or rulemaking to clarify MoCRA provisions related to adulteration, Amin Wasserman Gurnani attorney Angela Diesch suggested at the Independent Beauty Association’s Cosmetics Convergence Spring Symposium. Attendees also sought her take on whether the agency’s new recall authority is likely to spell an increase in cosmetic product recalls.
Medtronic Launches Remote Live-Stream Surgery, New AI Capabilities
Medtronic will launch a new feature that allows for live streaming of surgical procedures in more than 20 countries and the addition of 14 AI-driven algorithms to enhance surgical workflow.
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.